BC Week In Review | Mar 30, 2018
Clinical News

CHMP brushes off Radius osteoporosis treatment

EMA's CHMP recommended against approval of Radius' Eladynos abaloparatide-SC to treat osteoporosis in postmenopausal women at increased risk for fracture. Radius said it plans to request a re-examination. Abaloparatide-SC is a subcutaneous peptide analog of...
BC Innovations | Aug 21, 2014
Cover Story

Fat chance for cancer cachexia

With no drugs on the market and a pair of recent Phase III failures in cancer-associated cachexia, companies could be better off turning to the cause of the wasting disease rather than targeting its symptoms....
BC Innovations | Aug 14, 2014
Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Cachexia Parathyroid hormone-like hormone (PTHLH; PTHRP) In vitro and mouse studies suggest neutralizing PTHRP could help treat cancer-associated cachexia. In a mouse model of...
BC Innovations | Dec 1, 2011
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Parathyroid hormone-like hormone (PTHLH; PTHRP) Mouse studies suggest inhibiting PTHRP could help prevent breast tumor progression and metastasis. In a mouse model of...
Items per page:
1 - 4 of 4